Assessment of cytochrome P450 3A4-mediated drug–drug interactions for ipatasertib using a fit-for-purpose physiologically based pharmacokinetic model

PURPOSE: Ipatasertib, a potent and highly selective small-molecule inhibitor of AKT, is currently under investigation for treatment of cancer. Ipatasertib is a substrate and a time-dependent inhibitor of CYP3A4. It exhibits non-linear pharmacokinetics at subclinical doses in the clinical dose escala...

Descripción completa

Detalles Bibliográficos
Autores principales: Jing, Jing, Chen, Yuan, Musib, Luna, Jin, Jin Y., Cheung, Kit Wun Kathy, Yoshida, Kenta, Sane, Rucha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9054915/
https://www.ncbi.nlm.nih.gov/pubmed/35428895
http://dx.doi.org/10.1007/s00280-022-04434-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9054915/
https://www.ncbi.nlm.nih.gov/pubmed/35428895
http://dx.doi.org/10.1007/s00280-022-04434-2

Ejemplares similares